Inotiv

Ppara knockout rats

HsdSage:SD-Pparaem1Sage
Order Today
+1 800 793 7287
Description
Pricing
Technical resources
Cryopreserved

Typically heterozygous rats are cryo-recovered in 10-12 weeks to an age of 7 weeks old. Subsequently homozygous rats to an age of 7 weeks old can be produced within 20-22 weeks.
  • Background strain: Sprague Dawley
  • Homozygous knockout rats display total loss of protein via Western blot

Availability: Cryopreserved as heterozygous embryos
Zygosity: Homozygous as live colony

This model contains a bi-allelic deletion within the peroxisome proliferator-activated receptor alpha gene (Ppara).

Ppara (peroxisome proliferator-activated receptor alpha gene) is a ligand activated nuclear receptor, known to be activated by free fatty acids and their derivatives. Besides the studying of lipid metabolism and diabetes, Ppar-alpha affect the expression of target genes involved in cell proliferation, cell differentiation, and in immune and inflammation responses.


Origin: The Ppara KO rat model was originally created at SAGE Labs, Inc. in St. Louis, MO and distributed out of the Boyertown, PA facility. The line continues to be maintained through the original SAGE Labs animal inventory acquired by Envigo, then Envigo was acquired by Inotiv in 2021.

Available regions:

For pricing information, please contact us using the phone number above.

Research use and related publications
  • ADMET
  • Autoimmune disorders
  • Cell proliferation
  • Drug metabolism
  • Diabetes
  • Immunology
  • Inflammation
  • Lipid metabolism
  • Obesity
  • Wound healing
  • Xenobiotic

2025 Product guide

Receive a copy of our current research models and services product guide.

Download today  
SCIENCE Surgeon - clinical

SCIENTIFIC

INSIGHTS

Keep up-to-date with the latest industry thinking and scientific insights

Explore today
90-anni-globe-widget

More than 90 years of working together, to build a healthier and safer world

Explore our history
Decoration

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
Subscribe now